These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 21833453)

  • 1. Identification of thrombin-like activity in ovarian cancer associated ascites and modulation of multiple cytokine networks.
    Naldini A; Morena E; Belotti D; Carraro F; Allavena P; Giavazzi R
    Thromb Haemost; 2011 Oct; 106(4):705-11. PubMed ID: 21833453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stimulation of naïve monocytes and PBMCs with coagulation proteases results in thrombin-mediated and PAR-1-dependent cytokine release and cell proliferation in PBMCs only.
    Nieuwenhuizen L; Falkenburg WJ; Schutgens RE; Roosendaal G; van Veghel K; Biesma DH; Lafeber FP
    Scand J Immunol; 2013 May; 77(5):339-49. PubMed ID: 23421536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombin-mediated IL-10 up-regulation involves protease-activated receptor (PAR)-1 expression in human mononuclear leukocytes.
    Naldini A; Bernini C; Pucci A; Carraro F
    J Leukoc Biol; 2005 Sep; 78(3):736-44. PubMed ID: 15961578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells.
    Loercher AE; Nash MA; Kavanagh JJ; Platsoucas CD; Freedman RS
    J Immunol; 1999 Dec; 163(11):6251-60. PubMed ID: 10570318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombin and PAR-1-AP increase proinflammatory cytokine expression in C6 cells.
    Fan Y; Zhang W; Mulholland M
    J Surg Res; 2005 Dec; 129(2):196-201. PubMed ID: 16143343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of interleukin-12 expression by alpha-thrombin in human peripheral blood mononuclear cells: a potential mechanism for modulating Th1/Th2 responses.
    Naldini A; Aarden L; Pucci A; Bernini C; Carraro F
    Br J Pharmacol; 2003 Nov; 140(5):980-6. PubMed ID: 14517182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [-Cytokine level in malignant ascites and peripheral blood of patients with advanced ovarian carcinoma-].
    Radke J; Schmidt D; Böhme M; Schmidt U; Weise W; Morenz J
    Geburtshilfe Frauenheilkd; 1996 Feb; 56(2):83-7. PubMed ID: 8647364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian carcinoma cells and IL-1beta-activated human peritoneal mesothelial cells are possible sources of vascular endothelial growth factor in inflammatory and malignant peritoneal effusions.
    Stadlmann S; Amberger A; Pollheimer J; Gastl G; Offner FA; Margreiter R; Zeimet AG
    Gynecol Oncol; 2005 Jun; 97(3):784-9. PubMed ID: 15943987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
    Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
    J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation.
    Johnson K; Choi Y; DeGroot E; Samuels I; Creasey A; Aarden L
    J Immunol; 1998 May; 160(10):5130-5. PubMed ID: 9590265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Production of cytokines during interaction of peripheral blood mononuclear cells with autologous ovarian cancer cells or benign ovarian tumour cells.
    Nowak M; Klink M; Glowacka E; Sulowska Z; Kulig A; Szpakowski M; Szyllo K; Tchorzewski H
    Scand J Immunol; 2010 Feb; 71(2):91-8. PubMed ID: 20384860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Relationship between interleukin-10 level in ascites of patients with primary ovarian epithelial carcinoma and immune defect in peritoneal cavity].
    Zhou JW; Cheng Q; Xie X; Chen HZ; Ye DF; Lu WG
    Ai Zheng; 2004 May; 23(5):573-6. PubMed ID: 15142457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors.
    Nowak M; Glowacka E; Szpakowski M; Szyllo K; Malinowski A; Kulig A; Tchorzewski H; Wilczynski J
    Neuro Endocrinol Lett; 2010; 31(3):375-83. PubMed ID: 20588232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
    Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
    Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraperitoneal recombinant gamma-interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells.
    Allavena P; Peccatori F; Maggioni D; Erroi A; Sironi M; Colombo N; Lissoni A; Galazka A; Meiers W; Mangioni C
    Cancer Res; 1990 Nov; 50(22):7318-23. PubMed ID: 2121337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer.
    Mustea A; Pirvulescu C; Könsgen D; Braicu EI; Yuan S; Sun P; Lichtenegger W; Sehouli J
    Cytokine; 2008 Apr; 42(1):77-84. PubMed ID: 18329282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombin/thrombin receptor (PAR-1)-mediated induction of IL-8 and VEGF expression in prostate cancer cells.
    Liu J; Schuff-Werner P; Steiner M
    Biochem Biophys Res Commun; 2006 Apr; 343(1):183-9. PubMed ID: 16530725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity.
    Giuntoli RL; Webb TJ; Zoso A; Rogers O; Diaz-Montes TP; Bristow RE; Oelke M
    Anticancer Res; 2009 Aug; 29(8):2875-84. PubMed ID: 19661290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of interleukin-6 release from monocytes by serine proteinases and its potential mechanisms.
    Li T; Wang H; He S
    Scand J Immunol; 2006 Jul; 64(1):10-6. PubMed ID: 16784486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.